-
Mashup Score: 0De novo small-cell lung cancer transformation from KRAS G12C mutated lung adenocarcinoma with excellent response to sotorasib: a case report - 1 year(s) ago
The transformation to small-cell lung cancer (SCLC) is a known mechanism of resistance against molecularly targeted therapies. This study reports a patient with untreated lung adenocarcinoma, characterized by a Kirsten rat sarcoma viral oncogene homolog G12C mutation, that transformed into SCLC before treatment. Both the adenocarcinoma and SCLC components were responsive to sotorasib.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Interventions Designed to Increase the Uptake of Lung Cancer Screening: An Equity-Oriented Scoping Review - 1 year(s) ago
Participation in lung cancer screening (LCS) is lower in populations with the highest burden of lung cancer risk (through the social patterning of smoking behavior) and lowest levels of health care utilization (through structurally inaccessible care) leading to a widening of health inequities.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Impact of lymphopenia recovery after chemoradiotherapy on durvalumab consolidation therapy in stage III non-small cell lung cancer - 1 year(s) ago
Durvalumab maintenance therapy following definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III non-small cell lung cancer (NSCLC). Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of subsequent durvalumab therapy, data on the effect of TRL recovery on consolidation durvalumab therapy are lacking.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Lorlatinib is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ non-small cell lung cancer (NSCLC). There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Impact of lymphopenia recovery after chemoradiotherapy on durvalumab consolidation therapy in stage III non-small cell lung cancer - 1 year(s) ago
Durvalumab maintenance therapy following definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III non-small cell lung cancer (NSCLC). Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of subsequent durvalumab therapy, data on the effect of TRL recovery on consolidation durvalumab therapy are lacking.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Biopsy Method and Needle Size on Success of Next-Generation Sequencing in Non-Small Cell Lung Cancer: A Brief Report - 1 year(s) ago
Next generation sequencing (NGS) is essential to the care of patients with non-small cell lung cancer (NSCLC). However, NGS is dependent on adequate material from biopsy. We evaluated the impact of biopsy method and needle gauge necessary for optimizing success in tissue NGS.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The study (ClinicalTrials.gov, NCT04346914) is an open label, single-arm phase Ib clinical trial investigating the safety, tolerability, and efficacy of the recombinant human anti-programmed death-ligand 1 (PD-L1) monoclonal antibody Socazolimab in combination with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Good safety and efficacy…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Immune checkpoint inhibitors (ICIs) induce long-term, durable responses in patients with advanced non-small-cell lung cancer (NSCLC). However, these responses are limited to a minority of patients, and most responders show disease progression. The purpose of this study was to determine the differences in clinical factors and blood drug concentrations between LTRs (long-term responders) and…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Japanese subgroup analysis of CROWN - 1 year(s) ago
Lorlatinib, a third-generation ALK inhibitor, showed improved efficacy versus crizotinib in patients with previously untreated, advanced ALK-positive non-small cell lung cancer in the ongoing, global, randomized, phase 3 CROWN study.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Patients with cancer and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are underrepresented in several clinical trials testing immune checkpoint inhibitors (ICIs). Consequently, safety and efficacy of ICI therapy in this population have not been completely defined. We aimed to evaluate the attitudes of oncologists on this topic.
Categories: Hem/Oncs, Latest HeadlinesTweet
Interesting case in #JTOCRR of #KRAS G12C NSCLC with de novo #SCLC transformation from adenocarcinoma but both components responded to sotorasib. @JTOonline Need to learn more here. Note - this has *not* been my experience with transformed #EGFR NSCLC. https://t.co/SZfUA1apqI